Overview

Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
AstraZeneca
Treatments:
Lesogaberan
Proton Pump Inhibitors
Criteria
Inclusion Criteria:

- Provision of written informed consent

- At least 6 months history of Gastroesophageal reflux disease (GERD) symptoms

- Continuous treatment with Proton Pump Inhibitor (PPI)

- Ability to read and write

Exclusion Criteria:

- Prior surgery of the upper gastrointestinal (GI) tract

- History of clinically significant diseases other than GERD

- Need for concomitant medication with drugs that may influence gastrointestinal
symptoms